Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa GLPG2737 in Orkambi-treated adults with cystic fibrosis (F508del homozygous)
2017-002181-42Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing GLPG2737 + Orkambi with Placebo + Orkambi (2 arms). Primary endpoint: Change in sweat chloride concentration at Day 28. Started Jul 2017; status: completed.
02
Drugs
GLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-002181-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002181-42.